Clinical Trial Update: Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ZG006 in combination with PD-1/PD-L1 inhibitors as first-line therapy for extensive-stage small cell lung cancer. The study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• ZG006

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Small Cell Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING